CPPHA

CPPHA is potent and selective positive allosteric modulator (PAM) of the mGluR5 and mGluR1 (metabotropic glutamate receptor) . CPPHA can potentiate responses of mGluR5 and mGluR1 to activation of these receptors. CPPHA is developed for the research of central nervous system disorders[1][2].

Product Specifications

CAS Number

[693288-97-0]

UNSPSC

12352005

Hazard Statement

H400, H410

Target

MGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/CPPHA.html

Purity

98.06

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N(C(C2=CC=CC=C21)=O)CC3=CC(Cl)=CC=C3NC(C4=CC=CC=C4O)=O

Molecular Formula

C22H15ClN2O4

Molecular Weight

406.82

Precautions

H400, H410

References & Citations

[1]Liu F, et al. The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. Eur J Pharmacol. 2006 May 1;536 (3) :262-8.|[2]O'Brien JA, et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther. 2004 May;309 (2) :568-77.|[3]Zhang Y, et al. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther. 2005 Dec;315 (3) :1212-9.|[4]N-{4-Chloro-2-[ (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol. 2008 Mar;73 (3) :909-18.